1. Pre-treatment prediction of response to peginterferon plus ribavirin in chronic hepatitis C genotype 3
- Author
-
Pablo A Olivera, Melisa Dirchwolf, M.E. Sirotinsky, Silvia Borzi, Manuel Mendizabal, Diego Giunta, Julieta Trinks, M. Silva, Sebastián Marciano, Ezequiel Ridruejo, Adrián Gadano, Fernando Bessone, Omar Galdame, and Hugo Fainboim
- Subjects
medicine.medical_specialty ,CIENCIAS MÉDICAS Y DE LA SALUD ,Cirrhosis ,Sofosbuvir ,viruses ,Hepatitis C virus ,Medicina Clínica ,medicine.disease_cause ,Gastroenterology ,chemistry.chemical_compound ,Liver disease ,Retrospective Study ,Fibrosis ,Internal medicine ,purl.org/becyt/ford/3.2 [https] ,medicine ,Gastroenterología y Hepatología ,CIRRHOSIS ,Hepatology ,business.industry ,Ribavirin ,virus diseases ,medicine.disease ,digestive system diseases ,VIRAL LOAD ,SOFOSBUVIR ,chemistry ,SUSTAINED VIROLOGICAL RESPONSE ,Immunology ,purl.org/becyt/ford/3 [https] ,business ,DIRECT ANTIVIRAL AGENTS ,Body mass index ,Viral load ,medicine.drug - Abstract
AIM: To evaluate pre-treatment factors associated with sustained virological response (SVR) in patients with hepatitis C virus (HCV) genotype 3 treated with peginterferon and ribavirin (RBV). METHODS: We retrospectively analyzed treatment naive, mono-infected HCV genotype 3 patients treated with peginterferon and RBV. Exclusion criteria included presence of other liver disease, alcohol consumption and African American or Asian ethnicity. The variables collected and compared between patients who achieved an SVR and patients who did not were as follows: gender, age, fibrosis stage, diabetes, body mass index, steatosis, INFL3 polymorphism, pre-treatment HCV-RNA, type of peginterferon, RBV dose and adherence. RESULTS: A total of 107 patients treated between June, 2004 and March, 2013 were included. Mean treatment duration was 25.1 (± 1.8) wk. Overall, 58% (62/107) of the patients achieved an SVR and 42% (45/107) did not. In the multivariate logistic regression analysis, pre-treatment HCV-RNA ≥ 600000 UI/mL (OR = 0.375, 95%CI: 0.153-0.919, P = 0.032) and advanced fibrosis (OR = 0.278, 95%CI: 0.113-0.684, P = 0.005) were significantly associated with low SVR rates. In patients with pre-treatment HCV-RNA ≥ 600000 UI/mL and advanced fibrosis, the probability of achieving an SVR was 29% (95%CI: 13.1-45.2). In patients with pre-treatment HCV-RNA < 600000 UI/mL and mild to moderate fibrosis, the probability of achieving an SVR was 81% (95%CI: 68.8-93.4). CONCLUSION: In patients with HCV genotype 3 infections the presence of advance fibrosis and high pre-treatment viral load might be associated with poor response to peginterferon plus RBV. These patients could benefit the most from new direct antiviral agents-based regimes. Fil: Marciano, Sebastián. Hospital Italiano; Argentina Fil: Borzi, Silvia Mabel. Gobierno de la Provincia de Buenos Aires. Ministerio de Salud. Hospital Interzonal General de Agudos "prof. Dr. Rodolfo Rossi".; Argentina Fil: Dirchwolf, Melisa. Gobierno de la Ciudad de Buenos Aires. Hospital de Infecciosas "Dr. Francisco Javier Muñiz"; Argentina Fil: Ridruejo, Ezequiel. Universidad Austral. Hospital Universitario Austral; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. CEMIC-CONICET. Centro de Educaciones Médicas e Investigaciones Clínicas "Norberto Quirno". CEMIC-CONICET; Argentina Fil: Mendizabal, Manuel. Universidad Austral. Hospital Universitario Austral; Argentina Fil: Bessone, Fernando. Sanatorio del Parque. Unidad de Hepatología; Argentina Fil: Sirotinsky, María Ester. Hepatosur group; Argentina Fil: Giunta, Diego Hernan. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Hospital Italiano; Argentina Fil: Trinks, Julieta. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Hospital Italiano; Argentina Fil: Olivera Sendra, Pablo Andrés. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. CEMIC-CONICET. Centro de Educaciones Médicas e Investigaciones Clínicas "Norberto Quirno". CEMIC-CONICET; Argentina Fil: Galdame, Omar Andres. Hospital Italiano; Argentina Fil: Silva, Marcelo Oscar. Universidad Austral. Hospital Universitario Austral; Argentina. Hospital Italiano; Argentina Fil: Fainboim, Hugo. Gobierno de la Provincia de Buenos Aires. Ministerio de Salud. Hospital Interzonal General de Agudos "prof. Dr. Rodolfo Rossi".; Argentina Fil: Gadano, Adrián Carlos. Hospital Italiano; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
- Published
- 2015
- Full Text
- View/download PDF